Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
Status:
Completed
Trial end date:
2020-05-22
Target enrollment:
Participant gender:
Summary
This investigator driven study will examine the safety, efficacy and biological effects of
combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1
(PD-1), with stereotactic ablative body radiotherapy (SABR) for oligometastatic renal cell
carcinoma (RCC). The investigators hypothesise that the safety profile of this combination
will be clinically acceptable.